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Abstract
Cystinuria is a rare inherited renal stone disease. Mutations in two genes SLC3A1 and 
SLC7A9 underlie this condition, encoding proteins that facilitate dibasic amino acid 
exchange which are expressed in the gut and the proximal tubule of the kidney. Genetic 
studies now allow precise genotyping of patients who may have both autosomal domi-
nant and autosomal recessive patterns of disease. The disorder is characterised by the uri-
nary loss of cystine, lysine, ornithine, and arginine, and the insolubility of cystine gives 
rise to crystalluria and cysteine-containing renal stones. Although an inherited condition, 
it may present at any age. Clinical management combines lifestyle advice and preventa-
tive medical therapy. However, many patients require surgical interventions to remove 
problematic stones from the urinary tract. Preventative therapies include increased fluid 
intake, alkalinization of the urine, and the use of cystine-binding drugs, including peni-
cillamine and tiopronin, which form soluble heterodimers with cystine.
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1. Introduction
Cystinuria is an inherited metabolic disorder characterised by the abnormal transport of diba-
sic amino acids, cystine, lysine, ornithine and arginine, in the intestine and proximal renal 
tubule [1, 2]. In cystinuria patients these amino acids are excreted in excess concentrations in 
the urine due to a failure of reabsorption in the proximal tubule. Cystine is relatively insol-
uble; its presence in high concentrations in the urine predisposes to formation of urinary 
calculi, which are often large and can form staghorn calculi. On urine microscopy cystine 
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crystals appear as flat hexagonal crystals [2]. The recurrent formation of the cystine stones can 
lead to development of chronic kidney disease [3]. Ornithine, lysine and arginine are more 
soluble and therefore their excretion in excess concentrations in the urine does not produce 
clinical sequelae. There are currently no known clinical consequences of impaired absorption 
of these four dibasic amino acids within the intestine.
2. Diagnosis of cystinuria: historical and modern
Cystinuria may present with renal calculi at any age, but most patients will present before 30 
years of age. Historically, cystinuria was diagnosed mainly through renal calculi analysis and 
this lead to an underestimation of the incidence of the condition [1]. As methods developed to 
analyse the cystine concentration in urine samples it became possible to detect cases with con-
firmed accuracy, and also provided a valuable screening tool. The cyanide-nitroprusside reac-
tion, developed by Brand et al. in 1930, provided a qualitative method of measuring excessive 
urinary excretion of cystine [1]. This test is positive when the urinary cystine level is greater 
than 75 mg/g creatinine [2].
Modern diagnostic methods may utilise a combination of laboratory tests, stone composition 
analysis, radiological investigation and genetic testing. Urinary cystine levels may be pre-
cisely measured using mass spectrometry, and are significantly elevated in cystinuria patients 
[4]. Levels of urinary cystine has also been used historically to detect carrier status, but a 
molecular genetic diagnosis is more reliable in the modern era. On urine microscopy, hexago-
nal crystals can be visualised which are pathognomonic [3]. Cystine stones are faintly radio-
opaque and have a homogenous, ground-glass appearance [4], but may be missed on plain 
X-ray imaging. Cystine stones are often 100% cysteine but may contain variable amounts of 
calcium. CT-scanning allows accurate detection and localisation of cystine stones within the 
kidney and urinary tract.
3. Incidence and outcomes
Cystinuria is a rare inherited metabolic disorder, with an estimated incidence of 1:7000 live 
births [3]. The condition requires lifelong treatment, with the aim of minimising urinary cal-
culi formation. However, the treatments involving high fluid intake, dietary modification, 
and urinary alkalinisation may be burdensome for some patients and compliance may be 
difficult. In those patients who continue to form recurrent cystine stones there may be an 
associated decline in kidney function over time [5].
4. Genetics of cystinuria
Cystinuria is an inherited renal stone disorder. Traditionally, a classification system based upon 
phenotype grouped patients as type I, II or III according to the levels of urinary cystine excreted 
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by their parents, known to be obligate heterozygotes [5]. However, identification of the indi-
vidual mutations underlying cystinuria, in addition to recognised limitations of the phenotype-
based classification, has led to a new genotype-based classification system being introduced [6].
The heterodimeric amino acid transporter responsible for cystine absorption in the renal 
proximal tubule is formed by two proteins, b0,AT and rBAT, which are joined by a disulphide 
bridge [7]. The SLC3A1 gene, located on chromosome 2, encodes rBAT and mutations in both 
alleles (homozygous or compound heterozygous) of this gene lead to type AA cystinuria. 
The SLC7A9 gene, located on chromosome 19, encodes b0,AT and homozygous mutations in 
this gene produce type B cystinuria. Due to digenic inheritance of two or more mutant alleles 
there exist much rarer forms, including type AB, type ABB and type AAB cystinuria [8]. Such 
mutations account for only 2% of cases [7] (Table 1). Interestingly, patients with underlying 
mutations in SLC3A1 and SLC7A9 may sometimes present with calcium stones [9]. Genetic 
screening in paediatric stone formers may allow for precise diagnosis and earlier opportuni-
ties for therapeutic and preventative measures to be adopted [10].
Recently, a further membrane protein has been identified which is involved in cystine trans-
port in the S3 (distal) part of the proximal tubule; mutations in the gene encoding this protein 
could account for further cystinuria cases. The AGT1 protein is encoded by the SLC7A13 gene, 
and forms a heterodimer with rBAT to facilitate cystine reabsorption in the S3 part of the 
proximal tubule [11]. The discovery of AGT1 working alongside rBAT in the S3 section of the 
proximal tubule may help explain the previously recognised paradox of b0,AT and rBAT being 
predominantly expressed in different segments of the proximal tubule. It is known that b0,AT 
expression is highest in the S1 (proximal) segment of the proximal tubule, whilst rBAT expres-
sion is mostly in the S3 (distal) segment [11].
The clinical phenotype does not vary between the three recognised subtypes of cystinuria, 
although male gender and early age of stone onset have been suggested to be poor prognostic 
signs [1, 4]. As treatment options do not vary between genetic subtypes of cystinuria indi-
vidual genotyping has not been routinely performed in clinical practice [4].
5. Syndromes associated with cystinuria
There are three recessive contiguous gene syndromes associated with cystinuria. These are 
the hypotonia-cystinuria syndrome (HCS) [12], atypical hypotonia-cystinuria syndrome 
Gene OMIM id Inheritance pattern Cystinuria type
SLC3A1 104614 Autosomal dominant and 
recessive
Type A and type AA
SLC7A9 604144 Autosomal dominant and 
recessive
Type B and BB
2p21 deletion 606407 Autosomal recessive Hypotonia-cystinuria 
syndrome
Table 1. Known genetic causes of cystinuria.
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[13] and 2p21 deletion syndrome [4]. Each of these syndromes includes the homozygous 
 disruption of the SLC3A1 gene, and therefore produce cystinuria type AA as part of their 
clinical phenotype.
Hypotonia-cystinuria syndrome arises from homozygous deletion of two genes, SLC3A1 
and PREPL, and has the least severe phenotype. The main phenotypical features are infan-
tile hypotonia, poor sucking and associated feeding problems, growth hormone deficiency 
leading to growth restriction, mild facial dysmorphic features and cystinuria type AA [12]. 
Atypical hypotonia-cystinuria syndrome, which features disruption to three contiguous 
genes, SLC3A1, PREPL and C2orf34, produces an intermediate phenotype featuring mild to 
moderate intellectual disability in addition to the features of hypotonia-cystinuria syndrome 
[13]. The 2p21 deletion syndrome, resulting from homozygous loss of four contiguous genes, 
SLC3A1, PREPL, C2orf34 and PPM1B, produces a more severe phenotype, as expected, owing 
to the higher number of genes affected [4]. Patients with 2p21 deletion syndrome may have 
neonatal seizures, severe developmental delay and lactic acidosis in addition to the typical 
features associated with hypotonia-cystinuria syndrome (Table 1).
6. Biochemistry and urine analysis
Confirmation of significantly elevated urinary cystine levels is key to establishing a diagnosis 
of cystinuria. The cyanide-nitroprusside test is a qualitative test traditionally used as a screen-
ing test for cystinuria; a positive result occurs when the urine turns red after the addition of the 
reagent, indicating a urinary cystine level >75 mg/g creatinine [2]. However, as the cyanide-
nitroprusside test is designed to detect amino acids containing a free sulfhydryl or disulphide 
bond there is the possibility of obtaining a false positive result in cases of homocystinuria and 
acetonuria [4]. Precise quantitative measurement of urinary cystine levels is therefore always 
indicated in cystinuria patients, and homozygotes will often have grossly elevated levels of 
>300–400 mg/L, compared to the normal level of 30 mg/L [4]. In addition to measuring urinary 
cystine levels by mass spectrometry, urine microscopy may also be performed to look for the 
hexagonal colourless crystals which are pathognomonic for cystinuria [4].
7. Treatment of cystinuria
Cystinuria is an inherited metabolic disorder requiring lifelong treatment. In the absence of 
any specific treatment to reverse the abnormal dibasic amino acid transport, the target of ther-
apy is to prevent cystine stone formation and thereby minimise complications of recurrent 
nephrolithiasis. Management of patients should ideally be undertaken in dedicated metabolic 
stone clinics [14]. Initial treatment is focussed on increased fluid intake, dietary modifica-
tion and urinary alkalisation, but these interventions are cumbersome and patient compliance 
often limits their effectiveness. In refractory cases, a cystine-binding drug may be added to 
the treatment regime, although continued adherence to the initial conservative treatments is 
crucial for successful outcomes. Surgical intervention is reserved for large or symptomatic 
calculi which are causing obstruction, infection or pain.
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7.1. Fluid
Maintaining a high fluid intake, aiming to produce at least three litres of urine per day, is 
the cornerstone of successful cystinuria treatment. Establishing a hyperdiuresis reduces the 
cystine concentration in the urine, thereby reducing the risk of nephrolithiasis [4]. The thera-
peutic target is to keep urinary cystine levels below 300 mg/L [15]. Nocturnal intake of fluid, 
both before bed and ideally at least once overnight, is an important factor, in order to avoid 
the increased risk of stone formation associated with the body’s natural tendency to concen-
trate urine overnight [16]. However, it is hard for patients to comply with long-term [15]. 
Continued high fluid intake is a crucial factor in determining treatment success in cystin-
uria, both in isolation and in patients also taking thiol-binding drugs [15]; patient education 
regarding this is essential to achieve compliance with this burdensome intervention.
7.2. Diet
Dietary modification can help reduce the risk of stone formation in cystinuria. Patients are advised 
to follow a low sodium and relatively low animal protein diet. A low sodium diet is effective as 
dibasic amino acid reabsorption in the proximal tubule is partially sodium-dependent; a low 
sodium intake encourages reabsorption of cystine and sodium, thereby minimising excess uri-
nary cystine excretion [4]. A low animal protein, or ideally vegan diet, is advised as this leads to 
a more alkaline urine being produced and also reduces the intake of the amino acid methionine, 
which is the precursor to cysteine [16]. Recipe books have been written especially for cystinuric 
patients that provide ideas regarding foods with high fluid content and low animal protein [17].
7.3. Urinary alkalinisation
Cystine solubility is increased in alkaline pH; a target urinary pH of 7.0–7.5 is recommended 
in cystinuria patients [16]. This can be achieved either by supplementation with potassium 
citrate or sodium bicarbonate, or through following a vegan diet. Potassium citrate is the 
preferred medication, but its use is limited in patients with chronic renal impairment due to 
the risk of hyperkalemia. It is important for the urine to remain within the target pH range, 
as over-alkalinisation can paradoxically increase the risk of calcium stone formation. Patients 
can use urine dipsticks to regularly check their urine pH [16].
7.4. Cystine-binding thiol drugs
Thiol-containing medications (penicillamine, tiopronin and captopril) can play a role in cys-
tinuria treatment. These drugs bind to cystine in the urine, reducing the disulphide bond 
which forms cystine and producing two molecules of cysteine which are more soluble [4].
The use of penicillamine and tiopronin may be limited by their side-effect profile. Captopril, 
an angiotensin converting enzyme inhibitor, may be used as an alternative, although there 
is not strong evidence for its use in cystinuria [16]. Therapeutic success (reduction in stone 
events) is only likely to be achieved if conservative measures such as increased fluid intake 
are also followed simultaneously. Clinical trials using a new thiol binding drug called bucil-
lamine are underway and will be completed by March 2018 [18].




Although stone prevention is the aim of cystinuria management, in cases where medical 
therapy has failed minimally-invasive surgical intervention can be required to break up and 
remove stones. This may be through lithotripsy (or extracorporeal shock wave lithotripsy), ure-
teroscopy or percutaneous nephrolithotomy [16]. These techniques are similar to those used 
for other types of renal stones. However, extracorporeal shock wave lithotripsy may be less 
successful in cystinuria patients due to the recognised increased resistance of cystine stones 
to fragmentation by shock wave lithotripsy [4]. Cystinuria is a recognised form of staghorn 
calculus which may require open surgical intervention and even nephrectomy in some cases.
8. Conclusion
Although a rare inherited condition, cystinuria remains an important cause of renal calculi. 
Establishing the diagnosis is crucial in order to prevent further calculi formation in these patients, 
whose treatment is distinctly different to patients with the commoner calcium-containing cal-
culi. Our increasing understanding of the underlying genetic mutations causing cystinuria pro-
vides further information on the condition, and may eventually lead to treatments targeted at 
the underlying defect. However, at present, preventative medical treatment is the mainstay of 
treatment, reducing the calculi burden in cystinuria patients and aiming to avoid the risk of 
chronic renal impairment posed by recurrent calculi formation.
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